Cogent Biosciences, INC. (COGT) — SEC Filings

Q: What are the key financial highlights for Cogent Biosciences, INC.?

Key financial highlights for Cogent Biosciences, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Cogent Biosciences, INC.?

Key executives at Cogent Biosciences, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Cogent Biosciences, INC. stock?

Risk factors for Cogent Biosciences, INC. (COGT) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Cogent Biosciences, INC.?

Forward-looking statements and predictions from Cogent Biosciences, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Cogent Biosciences, INC.. Recent 8-K filing on Dec 8, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Cogent Biosciences, INC. on SEC EDGAR

Overview

Cogent Biosciences, INC. (COGT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 18, 2025: On November 18, 2025, Cogent Biosciences, Inc. entered into a material definitive agreement. This filing also indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement for the registrant. The company is involved in the pharmaceutical preparations

Sentiment Summary

Across 46 filings, the sentiment breakdown is: 3 bullish, 42 neutral, 1 mixed. The dominant filing sentiment for Cogent Biosciences, INC. is neutral.

Filing Type Overview

Cogent Biosciences, INC. (COGT) has filed 18 8-K, 5 10-Q, 2 DEF 14A, 1 10-K, 12 SC 13G/A, 4 SC 13D/A, 4 SC 13G with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (46)

8-K Filing — 8-K · Dec 8, 2025
Cogent Biosciences Enters Material Definitive Agreement — 8-K · Nov 18, 2025 Risk: medium
On November 18, 2025, Cogent Biosciences, Inc. entered into a material definitive agreement. This filing also indicates the creation of a direct financial oblig
8-K Filing — 8-K · Nov 13, 2025
Cogent Biosciences Files 8-K Report — 8-K · Nov 10, 2025 Risk: low
On November 10, 2025, Cogent Biosciences, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and
Cogent's Q3 Loss Widens Amid R&D Surge, Bolstered by Public Offering — 10-Q · Nov 7, 2025 Risk: high
Cogent Biosciences, Inc. reported a net loss of $80.93 million for the three months ended September 30, 2025, an increase from $70.63 million in the same period
Cogent Biosciences Files 8-K on Financials — 8-K · Nov 3, 2025 Risk: low
Cogent Biosciences, Inc. filed an 8-K on November 3, 2025, reporting on its results of operations and financial condition. The filing includes financial stateme
Cogent Biosciences Enters Material Agreement, Files 8-K — 8-K · Sep 11, 2025 Risk: medium
On September 5, 2025, Cogent Biosciences, Inc. entered into a material definitive agreement. This filing also indicates the creation of a direct financial oblig
Cogent Biosciences Files 8-K on Financials — 8-K · Aug 5, 2025 Risk: low
Cogent Biosciences, Inc. filed an 8-K on August 5, 2025, reporting on its results of operations and financial condition. The filing also includes financial stat
Cogent Biosciences Files 8-K: Material Agreement & Financials — 8-K · Jul 10, 2025 Risk: medium
On July 7, 2025, Cogent Biosciences, Inc. entered into a material definitive agreement. The company also reported its results of operations and financial condit
Cogent Biosciences Files 8-K: Other Events Reported — 8-K · Jul 7, 2025 Risk: medium
On July 7, 2025, Cogent Biosciences, Inc. filed an 8-K report. The filing indicates an 'Other Events' item, suggesting a significant, non-routine event has occu
Cogent Biosciences Files 8-K: Material Agreement & Financial Obligation — 8-K · Jun 11, 2025 Risk: medium
On June 11, 2025, Cogent Biosciences, Inc. entered into a material definitive agreement, likely related to financing or a significant business transaction. This
Cogent Biosciences Files 8-K with Corporate Updates — 8-K · Jun 5, 2025 Risk: low
Cogent Biosciences, Inc. filed an 8-K on June 5, 2025, reporting on events that occurred on June 4, 2025. The filing indicates amendments to articles of incorpo
Cogent Biosciences Files Q1 2025 10-Q — 10-Q · May 6, 2025 Risk: medium
Cogent Biosciences, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial status, including details on preferred stock
Cogent Biosciences DEF 14A: Executive Compensation Details — DEF 14A · Apr 22, 2025 Risk: low
Cogent Biosciences, Inc. filed its DEF 14A on April 22, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes
10-K Filing — 10-K · Feb 25, 2025
Pfizer to Acquire Cogent Biosciences for $6.7 Billion — 8-K · Dec 9, 2024 Risk: medium
Cogent Biosciences, Inc. announced on December 8, 2024, that it has entered into a definitive agreement to be acquired by Pfizer Inc. The transaction is valued
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
Cogent Biosciences Files Q3 2024 10-Q — 10-Q · Nov 12, 2024 Risk: medium
Cogent Biosciences, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial activities, including details related to
SC 13G/A Filing — SC 13G/A · Nov 7, 2024
Cogent Biosciences Files 8-K — 8-K · Sep 3, 2024 Risk: low
Cogent Biosciences, Inc. filed an 8-K on September 3, 2024, reporting other events and financial statements. The company, formerly Unum Therapeutics Inc., is in
Cogent Biosciences Files Q2 2024 10-Q — 10-Q · Aug 6, 2024 Risk: medium
Cogent Biosciences, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported research and development expenses for the six months ended Jun
Cogent Biosciences Files 8-K Report — 8-K · Jun 27, 2024 Risk: low
On June 27, 2024, Cogent Biosciences, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." It also no
Fairmount Funds Boosts Cogent Biosciences Stake to 11.4% — SC 13D/A · Jun 13, 2024 Risk: medium
Fairmount Funds Management LLC, through its affiliate Fairmount Healthcare Fund II GP LLC, has amended its Schedule 13D filing regarding Cogent Biosciences, Inc
Cogent Biosciences Files 8-K — 8-K · Jun 5, 2024 Risk: low
Cogent Biosciences, Inc. filed an 8-K on June 5, 2024, reporting on matters submitted to a vote of security holders and financial statements. The company, forme
Cogent Biosciences Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 7, 2024 Risk: medium
Cogent Biosciences, Inc. (COGT) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Cogent Biosciences, Inc. filed a 10-Q report for the quarter ended
Cogent Biosciences Announces 2024 Annual Meeting of Stockholders on June 5 — DEF 14A · Apr 23, 2024 Risk: low
Cogent Biosciences, Inc. (COGT) filed a Proxy Statement (DEF 14A) with the SEC on April 23, 2024. Cogent Biosciences will hold its 2024 Annual Meeting of Stockh
Fairmount Funds Amends Cogent Biosciences Stake — SC 13D/A · Apr 1, 2024 Risk: medium
Fairmount Funds Management LLC, through its affiliates Fairmount Healthcare Fund GP LLC and Fairmount Healthcare Fund II GP LLC, has amended its Schedule 13D fi
Fairmount Funds Amends Cogent Biosciences Stake — SC 13D/A · Mar 27, 2024 Risk: medium
Fairmount Funds Management LLC, through its group members Fairmount Healthcare Fund GP LLC and Fairmount Healthcare Fund II GP LLC, has amended its Schedule 13D
Cogent Biosciences Reports Unregistered Equity Sales — 8-K · Mar 22, 2024 Risk: medium
Cogent Biosciences, Inc. filed an 8-K on March 21, 2024, reporting unregistered sales of equity securities. The company, formerly Unum Therapeutics Inc., is inc
Cogent Biosciences Files 8-K on Financial Condition — 8-K · Feb 26, 2024 Risk: low
Cogent Biosciences, Inc. filed an 8-K on February 26, 2024, reporting on its results of operations and financial condition. The filing indicates the company's c
Fairmount Funds Amends Cogent Biosciences Stake — SC 13D/A · Feb 16, 2024 Risk: low
Fairmount Funds Management LLC, along with Fairmount Healthcare Fund GP LLC and Fairmount Healthcare Fund II GP LLC, filed an Amendment No. 3 to Schedule 13D on
Cogent Biosciences Files 8-K on Material Agreement & Equity Sales — 8-K · Feb 14, 2024 Risk: medium
Cogent Biosciences, Inc. filed an 8-K on February 14, 2024, reporting events that occurred on February 13, 2024. The filing indicates the company entered into a
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
SC 13G Filing — SC 13G · Feb 14, 2024
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
SC 13G Filing — SC 13G · Feb 13, 2024
TCG Crossover GP I Amends Cogent Biosciences Stake — SC 13G/A · Feb 9, 2024 Risk: low
TCG Crossover GP I, LLC, a Delaware-based entity, has filed an amendment to its Schedule 13G, indicating its ownership in Cogent Biosciences, Inc. as of Decembe
FMR LLC Discloses 6.157% Passive Stake in Cogent Biosciences — SC 13G · Feb 9, 2024 Risk: low
FMR LLC, a major investment management firm, and its Chair and CEO, Abigail P. Johnson, have reported a significant passive stake in Cogent Biosciences, Inc. As
Suvretta Capital Takes 5.0% Stake in Cogent Biosciences — SC 13G · Feb 5, 2024
Suvretta Capital Management, LLC, a Delaware-based investment firm, reported a significant stake in Cogent Biosciences, Inc. (NASDAQ: COGT) as of January 26, 20
BlackRock Amends Cogent Biosciences Stake (SC 13G/A) — SC 13G/A · Jan 26, 2024
BlackRock Inc. filed an amended SC 13G/A on January 26, 2024, disclosing its ownership in Cogent Biosciences, Inc. as of December 31, 2023. This amendment indic
State Street Corp Updates Passive Stake in Cogent Biosciences — SC 13G/A · Jan 23, 2024
State Street Corp, a major financial institution, filed an amended SC 13G/A on January 23, 2024, indicating its ownership of Cogent Biosciences, Inc. common sto

Risk Profile

Risk Assessment: Of COGT's 29 recent filings, 1 were flagged as high-risk, 15 as medium-risk, and 13 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Cogent Biosciences, INC.'s most recent 10-Q filing (Nov 7, 2025):

Revenue: N/A
Net Income: -$226.45M
EPS: N/A
Debt-to-Equity: 0.41
Cash Position: $390.89M
Operating Margin: N/A
Total Assets: $425.93M
Total Debt: $44.25M

Key Executives

Ms. Erin O'Connor
Erin O'Connor
Erin O’Connor
CHEN YU
Abigail P. Johnson

Industry Context

Cogent Biosciences operates in the highly competitive and capital-intensive biotechnology sector, specifically focusing on rare diseases and oncology. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Success hinges on innovation, clinical trial outcomes, and securing adequate funding to bring novel therapies to market.

Top Tags

8-K (6) · institutional-ownership (5) · material-agreement (4) · filing (4) · 10-Q (4) · financials (4) · biotech (4) · amendment (4) · financial-obligation (3) · sec-filing (3)

Key Numbers

Net Loss: $226.45M — Increased from $187.93M for the nine months ended September 30, 2024, indicating widening losses.
Research and Development Expenses: $194.22M — Increased from $170.61M for the nine months ended September 30, 2024, reflecting significant investment in pipeline.
Cash and Cash Equivalents: $125.30M — Increased from $98.17M at December 31, 2024, improving liquidity.
Short-term Marketable Securities: $265.59M — Increased from $188.91M at December 31, 2024, further strengthening the cash position.
Proceeds from Public Offering: $215.79M — Net proceeds from common stock issuance, a key financing activity.
Proceeds from Long-term Debt: $49.29M — New debt financing secured during the period.
Accumulated Deficit: $1.09B — Increased from $859.48M at December 31, 2024, highlighting ongoing unprofitability.
Common Stock Shares Outstanding: 139,827,662 — Increased from 110,461,729 at December 31, 2024, indicating significant dilution from offerings.
SEC File Number: 001-38443 — Identifies the company's filing history with the SEC.
EIN: 46-5308248 — Employer Identification Number for tax purposes.
Reporting Date: 2025-03-31 — End of the first quarter of 2025
Previous Year End: 2024-12-31 — End of fiscal year 2024
Quarter Start Date: 2025-01-01 — Beginning of the first quarter of 2025
Acquisition Value: $6.7B — Total cash amount Pfizer will pay for Cogent Biosciences.
Price Per Share: $11.50 — Cash amount Pfizer will pay for each outstanding share of Cogent Biosciences.

Forward-Looking Statements

{"claim":"TCG Crossover GP I, LLC will maintain its significant stake in Cogent Biosciences, Inc.","entity":"TCG Crossover GP I, LLC","targetDate":"Q2 2024","confidence":"medium"}
{"claim":"Cogent Biosciences, Inc. will continue to be a focus for institutional investors.","entity":"Cogent Biosciences, Inc.","targetDate":"Q4 2024","confidence":"medium"}
{"claim":"Other institutional investors may increase their positions in Cogent Biosciences, Inc.","entity":"Cogent Biosciences, Inc.","targetDate":"next 6-12 months","confidence":"medium"}

Related Companies

BLU · APLS · PRVB · PFE · CGNT · COG

Frequently Asked Questions

What are the latest SEC filings for Cogent Biosciences, INC. (COGT)?

Cogent Biosciences, INC. has 46 recent SEC filings from Jan 2024 to Dec 2025, including 18 8-K, 12 SC 13G/A, 5 10-Q. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of COGT filings?

Across 46 filings, the sentiment breakdown is: 3 bullish, 42 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Cogent Biosciences, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Cogent Biosciences, INC. (COGT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Cogent Biosciences, INC.?

Key financial highlights from Cogent Biosciences, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for COGT?

The investment thesis for COGT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Cogent Biosciences, INC.?

Key executives identified across Cogent Biosciences, INC.'s filings include Ms. Erin O'Connor, Erin O'Connor, Erin O’Connor, CHEN YU, Abigail P. Johnson.

What are the main risk factors for Cogent Biosciences, INC. stock?

Of COGT's 29 assessed filings, 1 were flagged high-risk, 15 medium-risk, and 13 low-risk.

What are recent predictions and forward guidance from Cogent Biosciences, INC.?

Recent forward-looking statements from Cogent Biosciences, INC. include guidance on {"claim":"TCG Crossover GP I, LLC will maintain its significant stake in Cogent Biosciences, Inc.","entity":"TCG Crossov and 2 other predictions.